ReviewNuclear medicine and molecular imaging2025
Fibroblast Activation Protein-Targeted Theranostics: Current Status in Clinical Development.
Review in Nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Homomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics: Design Principles, Structure-Function Relationships, and Preclinical Performance.Molecules (Basel, Switzerland) · 2026Review
- Molecular Imaging in Gastric Cancer: [¹⁸F]FDG and Fibroblast Activation Protein-Targeted PET/CT.Journal of gastric cancer · 2026Review
- Bridging the Gap in Theranostics: Where Do We Stand?Nuclear medicine and molecular imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibroblast activation protein (FAP) has attracted growing interest as a promising target for cancer imaging and therapy due to its highly selective expression in the tumor stroma. This review summarizes the current development status of FAP-targeted radioligand therapy based on clinical evidence reported to date. Early therapeutic pipelines utilized quinoline-based compounds such as FAPI-04 and FAPI-46, predominantly investigated for PET imaging, by labeling them with beta-emitting radionuclides. Despite high tumor uptake, these early agents showed limited therapeutic efficacy due to short tumor retention and insufficient intratumoral radiation dose. To overcome this limitation, various structural modifications have been investigated to improve tumor retention, including cyclic peptides, dimers, and albumin binders. Several of these modified agents have been evaluated in clinical studies, showing improved tumor dosimetry while maintaining acceptable normal organ doses and toxicity profiles. However, therapeutic outcomes remain inconclusive, and evidence from large-scale, well-structured studies is still lacking. Currently, a few compounds are under investigation in early-phase clinical trials aimed at regulatory approval for clinical use. Evidence of therapeutic efficacy from those strictly designed clinical trials is awaited.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.